Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Regulatory FDF Prices
NA
0
FDF
0
Weekly News Recap #Phispers


1. (3-o-hexyloxy)-tztp
2. 3-(3-o-hexyl-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine
3. Ly 246708
4. Ly-246708
5. Ly246708
6. Xanomeline Tartrate
1. 131986-45-3
2. 3-(hexyloxy)-4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazole
3. Ly 246708
4. Ly-246708
5. Ly246708
6. 3-hexoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole
7. 9ori6l73cj
8. Chembl21536
9. 5-(4-hexyloxy-[1,2,5]thiadiazol-3-yl)-1-methyl-1,2,3,6-tetrahydro-pyridine
10. Chebi:10056
11. Ly-246708 Free Base
12. 5-[4-(hexyloxy)-1,2,5-thiadiazol-3-yl]-1-methyl-1,2,3,6-tetrahydropyridine
13. Xanomeline (usan)
14. Xanomeline [usan]
15. Pyridine, 3-(4-(hexyloxy)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methyl-
16. Xanomeline [usan:inn]
17. Unii-9ori6l73cj
18. Lumeron
19. Memcor
20. Hexyloxy-tztp
21. Pyridine, 3-[4-(hexyloxy)-1,2,5-thiadiazol-3-yl]-1,2,5,6-tetrahydro-1-methyl-
22. Xanomeline [mi]
23. Xanomeline [inn]
24. Gtpl57
25. 3-(4-(hexyloxy)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine
26. Xanomeline [mart.]
27. Xanomeline [who-dd]
28. Schembl121046
29. Dtxsid60157286
30. Bcp31492
31. Ex-a6592
32. Zinc1532358
33. Bdbm50003359
34. Mfcd00867179
35. Akos016007489
36. Db15357
37. Sb18821
38. Nnc-11-0232
39. Ds-15663
40. Hy-105182
41. Cs-0025224
42. Ft-0602214
43. C72296
44. D06330
45. A888347
46. L000694
47. Q8042940
48. Ly-246708; Ly246708; Ly 246708
49. 3-(4-hexoxy-1,2,5-thiadiazol-3-yl)-1-methyl-5,6-dihydro-2h-pyridine
50. 3-(4-hexyloxy-1 ,2,5-thiadiazol-3-yl)-1 ,2,5,6-tetrahydro-1-methyl-pyridine
51. 5-(4-hexyloxy-[1,2,5]thiadiazol-3-yl)-1-methyl-1,2,3,6-tetrahydro-pyridine; Oxalic Acid
52. 5-[4-(hexyloxy)-1,2,5-thiadiazol-3-yl]-1-methyl-1,2,3,6-tetrahydropyridine, Aldrichcpr
53. 1018845-70-9
| Molecular Weight | 281.42 g/mol |
|---|---|
| Molecular Formula | C14H23N3OS |
| XLogP3 | 3.3 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 7 |
| Exact Mass | 281.15618354 g/mol |
| Monoisotopic Mass | 281.15618354 g/mol |
| Topological Polar Surface Area | 66.5 Ų |
| Heavy Atom Count | 19 |
| Formal Charge | 0 |
| Complexity | 298 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Muscarinic Agonists
Drugs that bind to and activate muscarinic cholinergic receptors (RECEPTORS, MUSCARINIC). Muscarinic agonists are most commonly used when it is desirable to increase smooth muscle tone, especially in the GI tract, urinary bladder and the eye. They may also be used to reduce heart rate. (See all compounds classified as Muscarinic Agonists.)
Parasympathomimetics
Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. (See all compounds classified as Parasympathomimetics.)
Psychotropic Drugs
A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). (See all compounds classified as Psychotropic Drugs.)
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 42043
Submission : 2025-05-31
Status : Active
Type : II
NDC Package Code : 70600-069
Start Marketing Date : 2025-05-20
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
| Available Reg Filing : ASMF |
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
✕ Product Not Available For Sales
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 43158
Submission : 2025-11-29
Status : Active
Type : II
NDC Package Code : 81666-010
Start Marketing Date : 2025-11-29
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT


FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 42043
Submission : 2025-05-31
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 43158
Submission : 2025-11-29
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC Package Code : 70600-069
Start Marketing Date : 2025-05-20
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 57572-0727
Start Marketing Date : 2024-11-25
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 81666-010
Start Marketing Date : 2025-11-29
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : Enaltec, founded in 2006, specializes in developing and manufacturing complex, small-volume, technology-driven APIs at competitive prices, leveraging the India advantage for global...
About the Company : Maithri Drugs Pvt. Ltd. is a global supplier of Active Pharmaceutical Ingredients (APIs), serving pharmaceutical companies in 60+ countries. Its API portfolio spans antivirals, ant...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
About the Company : Biophore, founded in 2007, develops and manufactures niche and complex pharmaceutical products. With USFDA- and EU-approved API facilities, a dedicated intermediates site and an R&...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
About the Company : HRV Pharma is a global manufacturer, seller, and exporter of APIs, intermediates, pellets, food-grade chemicals, food additives, and food ingredients. The company provides sourcing...
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
About the Company : Mankind Pharma was established in 1986 and began operating as a fully integrated pharmaceutical company in 1995. The company offers a broad portfolio across multiple therapeutic ca...
About the Company : ApiSyn Healthcare, established in 2017, is a vertically integrated manufacturer of APIs & intermediates serving the global pharmaceutical industry. As part of SynZeal Research, a p...
About the Company : Alfa Chemicals offers an all-encompassing range of solutions to the global pharmaceutical market, including contract manufacturing for intermediates & APIs; supply chain consolidat...

About the Company : Hunan Huateng Pharmaceutical Co., Ltd. is a research-based manufacturer and supplier of combinatorial building blocks, organics and fine chemicals, with 5000m2 laboratory and over ...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Cobenfy (Xanomeline) is a small molecule drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of schizophrenia.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Cobenfy
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Bristol Myers Squibb
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 20, 2026

Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
Details : Cobenfy (Xanomeline) is a small molecule drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of schizophrenia.
Product Name : Cobenfy
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 20, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Xanomeline is a small molecule drug, which is currently being evaluated in Phase III clinical studies for the treatment of schizophrenia.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Bristol Myers Squibb
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 20, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xanomeline is a small molecule drug, which is currently being evaluated in Phase III clinical studies for the treatment of schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 20, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Xanomeline, a miscellaneous product targeting M1 and M4 receptors, shows promise in treating schizophrenia.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Cobenfy
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 23, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zai Lab Receives China Approval for COBENFY in Schizophrenia
Details : Xanomeline, a miscellaneous product targeting M1 and M4 receptors, shows promise in treating schizophrenia.
Product Name : Cobenfy
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 23, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Xanomeline is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Schizophrenia.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 17, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xanomeline is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 17, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Xanomeline is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Autism Spectrum Disorder.
Lead Product(s): Xanomeline,Trospium Chloride,KarX-EC
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 16, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Xanomeline,Trospium Chloride,KarX-EC
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism
Details : Xanomeline is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Autism Spectrum Disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 16, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Xanomeline is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Autism Spectrum Disorder.
Lead Product(s): Xanomeline,Trospium Chloride,KarX-EC
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 16, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Xanomeline,Trospium Chloride,KarX-EC
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xanomeline is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Autism Spectrum Disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 16, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Xanomeline is a small molecule candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of undefined medical condition.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 02, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
KarXT Concentrations in the Breast Milk and Plasma of Lactating Females
Details : Xanomeline is a small molecule candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 02, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Xanomeline is a small molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Schizophrenia.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 28, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Effect of KarXT on Urological Safety
Details : Xanomeline is a small molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 28, 2025

Details:
Xanomeline is a small molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Alzheimer Disease.
Lead Product(s): Xanomeline,Trospium Chloride,Lecanemab
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Bristol Myers Squibb
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 08, 2025

Lead Product(s) : Xanomeline,Trospium Chloride,Lecanemab
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xanomeline is a small molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 08, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Xanomeline is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Anemia, Sickle Cell.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 02, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xanomeline is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Anemia, Sickle Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 02, 2025

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
ABOUT THIS PAGE
67
PharmaCompass offers a list of Xanomeline API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Xanomeline manufacturer or Xanomeline supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Xanomeline manufacturer or Xanomeline supplier.
PharmaCompass also assists you with knowing the Xanomeline API Price utilized in the formulation of products. Xanomeline API Price is not always fixed or binding as the Xanomeline Price is obtained through a variety of data sources. The Xanomeline Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A xanomeline tartrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of xanomeline tartrate, including repackagers and relabelers. The FDA regulates xanomeline tartrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. xanomeline tartrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of xanomeline tartrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A xanomeline tartrate supplier is an individual or a company that provides xanomeline tartrate active pharmaceutical ingredient (API) or xanomeline tartrate finished formulations upon request. The xanomeline tartrate suppliers may include xanomeline tartrate API manufacturers, exporters, distributors and traders.
click here to find a list of xanomeline tartrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A xanomeline tartrate DMF (Drug Master File) is a document detailing the whole manufacturing process of xanomeline tartrate active pharmaceutical ingredient (API) in detail. Different forms of xanomeline tartrate DMFs exist exist since differing nations have different regulations, such as xanomeline tartrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A xanomeline tartrate DMF submitted to regulatory agencies in the US is known as a USDMF. xanomeline tartrate USDMF includes data on xanomeline tartrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The xanomeline tartrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of xanomeline tartrate suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing xanomeline tartrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for xanomeline tartrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture xanomeline tartrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain xanomeline tartrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a xanomeline tartrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of xanomeline tartrate suppliers with NDC on PharmaCompass.
xanomeline tartrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of xanomeline tartrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right xanomeline tartrate GMP manufacturer or xanomeline tartrate GMP API supplier for your needs.
A xanomeline tartrate CoA (Certificate of Analysis) is a formal document that attests to xanomeline tartrate's compliance with xanomeline tartrate specifications and serves as a tool for batch-level quality control.
xanomeline tartrate CoA mostly includes findings from lab analyses of a specific batch. For each xanomeline tartrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
xanomeline tartrate may be tested according to a variety of international standards, such as European Pharmacopoeia (xanomeline tartrate EP), xanomeline tartrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (xanomeline tartrate USP).